Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases

INTRODUCTION: The CORE study aimed to provide a detailed understanding of real-world immune globulin subcutaneous (human) 20% solution (Ig20Gly) utilization in patients with primary immunodeficiency diseases (PIDs) in Germany and Switzerland. METHODS: Patients with PIDs receiving a stable dose of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Fasshauer, Maria, Borte, Michael, Bitzenhofer, Michaela, Pausch, Christine, Pittrow, David, Park, Michelle, Gladiator, André, Jandus, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611600/
https://www.ncbi.nlm.nih.gov/pubmed/37751025
http://dx.doi.org/10.1007/s12325-023-02649-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611600/
https://www.ncbi.nlm.nih.gov/pubmed/37751025
http://dx.doi.org/10.1007/s12325-023-02649-0

Ejemplares similares